Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma-Reference-Cited by-同舟云学术

Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma

Published:2016-12 Issue:6 Volume:102 Page:1821-1828
ISSN:0003-4975
Container-title:The Annals of Thoracic Surgery
language:en
Short-container-title:The Annals of Thoracic Surgery

Author:

Isaka Tetsuya,Nakayama Haruhiko,Yokose Tomoyuki,Ito Hiroyuki,Miyagi Yohei,Matsuzaki Tomohiko,Nagata Masashi,Furumoto Hideyuki,Nishii Teppei,Katayama Kayoko,Yamada Kouzo,Masuda Munetaka

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference32 articles.

1. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions;Pao;J Clin Oncol,2005

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

4. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013

5. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial;Wu;Lancet Oncol,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-6 and epidermal growth factor as noninvasive biomarkers of progression in chronic glomerulonephritis;American Journal of Physiology-Cell Physiology;2023-11-01

2. Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1–N2 epidermal growth factor receptor mutant lung adenocarcinoma;Translational Lung Cancer Research;2023-10

3. A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer;Cancers;2023-09-14

4. The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma;The Annals of Thoracic Surgery;2023-06

5. Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report;International Journal of Cancer Care and Delivery;2022-07-23